Postdoc to study T cell therapy of cancer in humanized mice
The candidate will be expected:
- to independently design and perform experiments
- develop a firm grasp of the scientific literature
- present and discuss results
- write scientific articles.
Recent years have revealed the power of the immune system in the fight against cancer (Science. 2013 342:1432). Transfusion of in vitro expanded Tumor Infiltrating Lymphocytes (TILs) or T cells with chimeric antigen receptors (CAR T cells) into patients constitute promising forms of therapy for hitherto untreatable types of cancer (Mol Oncol. 2015, 9:1918; Curr Opin Immunol. 2016, 41:68). Together with the Laboratory for Cellular Therapy at Sanquin and physicians at the Netherlands Cancer Institute, we aim to improve the quality of adoptive T cell therapy of cancer and to generate novel T cell based therapies against lung, renal and prostate cancer.
A hurdle for the development of novel treatments consists of the difficulty to translate in vitro findings to the complexity of cancer in vivo. We are therefore looking for a postdoc to study responses of TILs or CAR T cells to autologous patient derived tumors
in a humanized mouse model. For this, we will make use of next generation humanized mice (MISTRG, Nat Biotechnol. 2014 32:364), in which multiple murine cytokine genes have been replaced by their human counterparts to allow optimal human hematopoiesis.
Where you will work:
Sanquin Research performs basic, applied, and clinically oriented research in the field of blood and blood transfusion. Our research is focussed on haematology, blood coagulation, immunology, cellular therapies and donor studies. Sanquin offers an international, competitive, multidisciplinary research environment with state-of-the-art facilities. The postdoc will be employed in the group of Dr. Derk Amsen, who has had a longstanding interest in T cell immunology (Cell 2004 117:515; Immunity 2007 27:89; Nat Immunol. 2014, 15: 1143; Nat Immunol. 2016, in press). This is a joint project with Drs. Monika Wolkers, Robbert Spaapen and Patrick Burger at Sanquin and immuno-oncologist Dr. John Haanen at the Netherlands Cancer Institute (Science. 2004, 304:1314; Sci Transl Med. 28:200ra116, Nat Rev Cancer. 2015, 15:457). Furthermore, there will be close collaboration with Dr. Hergen Spits at the Academic Medical Center, Dr. Richard Flavell (Yale University) and Dr. Anthony Rongvaux (Fred Hutchinson Cancer Center), pioneers in the field of humanized mice.
We are looking for:
- A PhD in Immunology or related relevant field and experience with in vivo mouse experiments.
- We are looking for an ambitious postdoctoral fellow with a strong background in mouse Immunology.
- We offer 3 years of funding in a vibrant highly international and multidisciplinary scientific environment.
- The Netherlands Cancer Institute and the Sanquin Landsteiner Laboratory for Blood Research reside in the Slotervaart Medical Campus in Amsterdam.
- Together, the institutes possess state-of-the-art facilities for genomics, proteomics and mouse genetics as well as direct access to patient material.
- The close collaboration with physicians at The Netherlands Cancer Institute furthermore provides prime opportunities implement promising research findings for direct patient benefit.
- salary conform CAO Sanquin;
- a temporary position for 36 months;
- 8,33% end-of-year bonus;
- partial reimbursement of travel costs;
- pension plan with Pensioenfonds Zorg & Welzijn (PFZW);
- collective discounts on various insurances;
- at fulltime employment (36 hours) 201 hours of leave per annum.
Interesse in de functie van Postdoc to study T cell therapy of cancer in humanized mice bij Sanquin Bloedvoorziening in Amsterdam?
Reageer voor 5 november 2016 met je CV en motivatie via de bovenstaande ''solliciteer direct'' button.